Phase 2a Immunogenicity Study of Hantaan/Puumala Virus DNA Vaccine for Prevention of Hemorrhagic Fever

Inclusion Criteria:

- Healthy adult male or non-pregnant, non-lactating female, ages 18-49 (inclusive) at
the time of screening

- Have provided written informed consent before screening

- Free of clinically significant health problems, as determined by pertinent medical
history and clinical examination prior to entry into the study

- Available and able to participate for all study visits and procedures

- Females, if sexually active, are known to be at least one year post-menopausal
(defined as no menses for 12 consecutive months), or willing to use an effective
method of contraception (eg, hormonal contraception, diaphragm, cervical cap,
intrauterine device, condom, anatomical sterility [self or partner]) from the date of
screening until at least 3 months after the last injection

- Negative hantavirus pseudovirion neutralization assay (PsVNA) test result at screening

Exclusion Criteria:

- History or serologic evidence of prior infection with any hantavirus virus, or prior
participation in a HTNV or PUUV vaccine trial

- History of severe local or systemic reactions to any vaccination or a history of
severe allergic reactions

- Ongoing participation in another clinical trial

- Receipt or planned receipt of any vaccination, experimental or otherwise within the
period 30 days prior to the first injection through the period 60 days after Study Day
168 (booster dose; approximately 9 month period in total), with the exception of
emergency use vaccinations as needed

- Individuals in whom a skinfold measurement of the cutaneous and subcutaneous tissue
for all eligible injection sites (deltoid region) exceeds 40 mm

- Individuals in whom the ability to observe possible local reactions at the eligible
injections sites (deltoid region) is, in the opinion of the investigator, unacceptably
obscured due to a physical condition or permanent body art

- Acute or chronic, clinically significant hematologic, pulmonary, cardiovascular, or
hepatic or renal functional abnormality as determined by the investigator based on
medical history, physical exam, electrocardiogram (ECG), and/or laboratory screening
test

- Pregnant or lactating female, or female who intends to become pregnant during the
study period

- Administration of immunoglobulins and/or any blood products within the 120 days
preceding study entry or planned administration during the study period

- Any serologic evidence of hepatitis B or C infection

- Any confirmed or suspected immunosuppressive or immunodeficient condition, including
human immunodeficiency virus (HIV) infection

- Administration of chronic (defined as more than 14 days) immunosuppressants or other
immune modifying drugs within 6 months of study entry

1. For corticosteroids, this will mean prednisone, or equivalent, greater than or
equal to 0.5 mg/kg/day

2. Intranasal and topical steroids are allowed

- Any chronic or active neurologic disorder, including seizures and epilepsy, excluding
a single febrile seizure as a child

- Syncopal episode within 12 months of screening

- Suspected or known current alcohol and/or illicit drug abuse

- Unwilling to allow storage and use of blood for future hantavirus-related research

- Any other significant finding that in the opinion of the investigator would increase
the risk of the individual having an adverse outcome from participating in this study